AirJoule Technologies Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AirJoule Technologies Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.04M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $215.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.38M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.04M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($544.2K) | Apr 17, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.59M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($65.91M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.39M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.34M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($545.1K) | Apr 17, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.02M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.31M | Mar 25, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 9, 2021 | $20.0K | Apr 13, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.63M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($24.26M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($5.10M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.72M) | Mar 11, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $19.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $99.0K | Mar 25, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.64M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $369.85M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $556.1K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $295.97M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $293.83M | Apr 17, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $117.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.46M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $11.86M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $11.77M | Apr 17, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $267.94M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $252.11M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($5.90M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $5.16M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | ($8.31M) | Mar 11, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $198.53M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($17.17M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($9.19M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($8.31M) | Apr 17, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $59.2K | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $1.29M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $2.84M | Apr 17, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Apr 13, 2022 |